Best Sellers
  • DSIP Original price was: £34.99.Current price is: £31.99.mg
  • GHK-Cu (Pen) Price range: £74.99 through £94.99
  • SLU-PP-332 £79.99
  • GHRP-6 Original price was: £19.99.Current price is: £17.99.mg
  • AOD 9604 Price range: £39.99 through £69.99mg

AOD 9604

Price range: £39.99 through £69.99mg

AOD-9604

Hormonal — GH Fragment – Tyr-hGH(177-191)

AOD-9604 is a modified C-terminal fragment of human growth hormone developed to isolate lipolytic properties without stimulating IGF-1 or producing the anabolic side effects of full-length GH. Received GRAS status from the FDA as a food additive ingredient.

Fragment of hGH aa 177–191
IGF-1 Effect: None observed
Primary Research: Fat metabolism
Select options This product has multiple variants. The options may be chosen on the product page

BPC-157

£64.99mg
Select options This product has multiple variants. The options may be chosen on the product page

GHK-Cu (Pen)

Price range: £74.99 through £94.99

GHK-Cu

Cosmetic — Copper Carrier Peptide
Gly-His-Lys · Cu²⁺

GHK-Cu is a naturally occurring copper peptide first isolated from human plasma in 1973. It upregulates over 4,000 human genes, stimulates collagen synthesis, exerts antioxidant effects, and demonstrates broad anti-inflammatory activity. A well-established topical cosmetic ingredient with growing interest in systemic applications.

Discovery:
1973, Loren Pickart
Genes Modulated:
>4,000
Key Metal:
Copper (Cu²⁺)
Select options This product has multiple variants. The options may be chosen on the product page

Retatrutide (Pen)

Price range: £54.99 through £124.99

Retatrutide

Metabolics & GLP-1 — Triple Agonist
GIP/GLP-1/GCG triple agonist peptide

Retatrutide is an investigational once-weekly triple agonist of the GIP, GLP-1, and glucagon receptors (triple G). In the Phase II SURMOUNT dose-finding trial, 12 mg weekly produced mean body weight loss of 24.2% at 48 weeks — the highest reported for any pharmacological agent in a controlled trial.

Mechanism:
GIP + GLP-1 + glucagon triple agonist
Stage:
Phase III trials (as of 2026)
Peak Phase II Weight Loss:
24.2% at 48 weeks

Select options This product has multiple variants. The options may be chosen on the product page